Biogen Inc. closed 48.82% short of its 52-week high of $238.00, which the company reached on July 12th.

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Biogen Inc.’s chief executive officer said that the impact from US tariffs will be limited, as three-quarters of its product ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Shares of Biogen Inc. BIIB rose 2.15% to $123.53 Friday, on what proved to be an all-around great trading session for the ...

EPS: US$1.65 (down from US$2.71 in 1Q 2024). Our free stock report includes 2 warning signs investors should be aware of before investing in Biogen. Read for free now. Revenue exceeded analyst ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including ...

In April 2025, Pfizer organized a study is to learn about the effects, safety and how PF-06823859 is processed in adults with ...

My name is Melinda, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Biogen first quarter 2025 earnings call and business update. (Operator Instructions).

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...